Anti-interleukin-2 receptor monoclonal antibody LO-Tact-1

Drug Profile

Anti-interleukin-2 receptor monoclonal antibody LO-Tact-1

Alternative Names: Anti-CD25 monoclonal antibody LO-Tact-1; Interleukin-2 receptor monoclonal antibody LO-Tact-1; LO-Tact-1

Latest Information Update: 02 Jul 1999

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Nonindustrial source
  • Class Monoclonal antibodies
  • Mechanism of Action Interleukin 2 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Graft-versus-host disease

Most Recent Events

  • 02 Jul 1999 No-Development-Reported for Graft-versus-host disease in Belgium (IV-infusion)
  • 28 Aug 1996 A study has been added to the Transplant Rejection therapeutic trials section .
  • 20 Mar 1996 New profile
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top